Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $9.50.

A number of research analysts have issued reports on QNCX shares. D. Boral Capital reissued a “buy” rating and issued a $12.00 price target on shares of Quince Therapeutics in a report on Wednesday, February 5th. Rodman & Renshaw started coverage on Quince Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $11.00 target price for the company. Maxim Group started coverage on Quince Therapeutics in a research note on Thursday, November 7th. They set a “buy” rating and a $6.00 target price for the company. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Finally, Brookline Capital Management started coverage on Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price for the company.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in QNCX. Northern Trust Corp grew its holdings in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after buying an additional 16,501 shares in the last quarter. Anfield Capital Management LLC purchased a new stake in Quince Therapeutics in the 4th quarter valued at $50,000. Virtu Financial LLC purchased a new position in shares of Quince Therapeutics during the 4th quarter worth $55,000. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics during the 4th quarter worth $57,000. Finally, Geode Capital Management LLC grew its holdings in shares of Quince Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock worth $703,000 after purchasing an additional 36,807 shares during the period. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Trading Down 5.0 %

Shares of NASDAQ:QNCX opened at $1.33 on Friday. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45. The company has a market capitalization of $58.52 million, a PE ratio of -1.07 and a beta of 0.61. The business has a 50 day moving average of $1.65 and a two-hundred day moving average of $1.33. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.